Primary Job Title Chief Executive Officer Primary Organization Apimeds Pharmaceuticals
Location Matawan, New Jersey, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Erik Emerson is based out of Matawan, New Jersey and is the Chief Executive Officer of Apimeds Pharmaceuticals. He most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had founded in 2013. He had led Symplmed to the submission, approval and commercial launch of PrestaliaR, and to the eventual sale
of such assets to Marina Biotech in June 2017. He also spearheaded the development and launch of Symplmed’s DyrctAxess technology, a patented software designed to manage prescription fulfillment and patient monitoring. DyrctAxess has demonstrated a significant impact on patient conversion to treatment, long-term compliance and overall patient retention. Prior to founding Symplmed, Mr. Emerson served as the head of Commercial Development at XOMA from 2010 to 2013; and as Director of Marketing at Gilead Sciences from 2007 to 2010. He began his career at King Pharmaceuticals in sales, sales training and marketing. Mr. Emerson graduated from the University of Oregon with a Bachelor of Arts in Political Science with a specialization in Administration and Organization.
